CD274 and nasopharyngeal carcinoma: Similarly, the phase III JUPITER-02 study evaluated the predictive value of PD-L1 expression in patients with advanced NPC and found a clinical benefit from the combination of PD-1 inhibitor and GP regimen regardless of PD-L1 expressions [19].